Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Trial Profile

Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genmab; Janssen-Cilag
  • Most Recent Events

    • 12 Dec 2017 Results from GEN501 and Sirius trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Oct 2017 Results evaluating the effect of daratumumab alone or in combination with lenalidomide-dexamethasone using data from GEN501 and GEN503 trials published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 05 Oct 2017 Results (n=228) of exploratory analysis assessing the influence of disease and patient characteristics on exposure to daratumumab and clinical outcomes using patient data from GEN501 and SIRIUS trials published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top